Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1468748 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $40.29Day −3.87%Mkt cap $2.5B1Y +389.0%Off 52W high −15.8%Vol (1Y) 132.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,957 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest16.6% of sh out |
| Days to cover13.7d |
| 13F net flow (QoQ)+1.79% |
| Top-10 13F concentration65.0% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$230.7M |
| ROE−149.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+44.1% |
| 1Y+389.0% |
| 3Y+1303.8% |
| 5Y−56.1% |
| Since incept. (ann.)+19.3% |
Total return through 2026-07-28 · series begins 2018-10-04. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)132.8% |
| Ann. volatility (3Y)114.9% |
| Sharpe (1Y)1.78 |
| Sharpe (3Y)1.30 |
| Max drawdown (1Y)−36.2% |
| Max drawdown (3Y)−81.1% |
| Beta (3Y vs SPY)2.39 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 19.9M | $759M | 31.83% | +0.0% |
| BlackRock, Inc. | 3.9M | $150M | 6.29% | −0.5% |
| STATE STREET CORP | 2.3M | $86M | 3.60% | +30.0% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.0M | $78M | 3.26% | +74.3% |
| BRAIDWELL LP | 1.8M | $69M | 2.91% | −12.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $65M | 2.74% | new |
| GOLDMAN SACHS GROUP INC | 1.7M | $64M | 2.70% | +29.6% |
| RTW INVESTMENTS, LP | 1.5M | $57M | 2.38% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.94 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$1.16 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$1.03 | — | — | — |
| 2025-03-31 | 2025-05-14 | −$1.09 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
